{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:37:27Z","timestamp":1786653447895,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Impetigo is a common childhood skin infection. There are reports of increasing drug resistance to the currently used topical antibiotics including fusidic acid and mupirocin. Retapamulin is a newer topical agent of pleuromutilin class approved by the Food and Drug Administration for treatment of impetigo in children and has been recently made available in the Indian market. It has been demonstrated to have low potential for the development of antibacterial resistance and a high degree of potency against poly drug resistant Gram-positive bacteria found in skin infections including\n                      <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                      strains. The drug is safe owing to low systemic absorption and has only minimal side-effect of local irritation at the site of application.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0022-3859.113842","type":"journal-article","created":{"date-parts":[[2013,6,21]],"date-time":"2013-06-21T06:07:48Z","timestamp":1371794868000},"page":"127-130","source":"Crossref","is-referenced-by-count":6,"title":["Retapamulin"],"prefix":"10.4103","volume":"59","author":[{"given":"D","family":"Dhingra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Parakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20240205","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00148581-200507020-00002","article-title":"Staphylococcal skin infections in children: Rational drug therapy recommendations","volume":"7","author":"Ladhani","year":"2005","journal-title":"Paediatr Drugs"},{"key":"R2-9-20240205","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/0378-6323.58693","article-title":"Retapamulin: A novel topical antibiotic","volume":"76","author":"Nagabushan","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R3-9-20240205","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2217\/17460913.2.6.591","article-title":"Retapamulin: A semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children","volume":"2","author":"Jacobs","year":"2007","journal-title":"Future Microbiol"},{"key":"R4-9-20240205","first-page":"41","article-title":"Topical retapamulin in the management of infected traumatic skin lesions","volume":"5","author":"Shawar","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"R5-9-20240205","first-page":"1198","article-title":"Retapamulin: An antibacterial with a novel mode of action in an age of emerging resistance to staphylococcus aureus","volume":"9","author":"Weinberg","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"R6-9-20240205","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1529-8019.2008.00190.x","article-title":"Local antibiotics in dermatology","volume":"21","author":"Gelmetti","year":"2008","journal-title":"Dermatol Ther"},{"key":"R7-9-20240205","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jac\/dkm019","article-title":"In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections","volume":"59","author":"Odou","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R8-9-20240205","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2165\/00003495-200868060-00008","article-title":"Retapamulin: A review of its use in the management of impetigo and other uncomplicated superficial skin infections","volume":"68","author":"Yang","year":"2008","journal-title":"Drugs"},{"key":"R9-9-20240205","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2165\/0128071-200809060-00010","article-title":"Spotlight on retapamulin in impetigo and other uncomplicated superficial skin infections","volume":"9","author":"Yang","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"R10-9-20240205","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2310\/6620.2009.09003","article-title":"Allergic contact dermatitis from retapamulin ointment","volume":"20","author":"Warshaw","year":"2009","journal-title":"Dermatitis"},{"key":"R11-9-20240205","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jaad.2006.08.058","article-title":"Topical retapamulin ointment (1%, wt\/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: Results of a randomized controlled trial","volume":"55","author":"Parish","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R12-9-20240205","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1540-9740.2006.05774.x","article-title":"Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin","volume":"5","author":"Free","year":"2006","journal-title":"Skinmed"},{"key":"R13-9-20240205","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000107776","article-title":"Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: A randomized, observer-blinded, noninferiority study","volume":"215","author":"Oranje","year":"2007","journal-title":"Dermatology"},{"key":"R14-9-20240205","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1365-2133.2008.08485.x","article-title":"Efficacy and safety of retapamulin ointment as treatment of impetigo: Randomized double-blind multicentre placebo-controlled trial","volume":"158","author":"Koning","year":"2008","journal-title":"Br J Dermatol"},{"key":"R15-9-20240205","first-page":"858","article-title":"Efficacy and tolerability of retapamulin 1% ointment for the treatment of infected atopic dermatitis: A pilot study","volume":"11","author":"Kircik","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"R16-9-20240205","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1128\/AAC.01432-05","article-title":"Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci","volume":"50","author":"Jones","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-9-20240205","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/jac\/dkn266","article-title":"In vitro activity of retapamulin against staphylococcus aureus isolates resistant to fusidic acid and mupirocin","volume":"62","author":"Woodford","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R18-9-20240205","first-page":"127","article-title":"In vitro activity of retapamulin against linezolid and methicillin-resistant staphylococcus aureus isolates","volume":"24","author":"Candel","year":"2011","journal-title":"Rev Esp Quimioter"},{"key":"R19-9-20240205","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1128\/AAC.00399-08","article-title":"Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent","volume":"52","author":"Traczewski","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-9-20240205","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1128\/AAC.01665-10","article-title":"In vitro activities of retapamulin and 16 other antimicrobial agents against recently obtained Streptococcus pyogenes isolates","volume":"55","author":"P\u00e9rez-Trallero","year":"2011","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005257-201359020-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:37:31Z","timestamp":1786649851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005257-201359020-00009"}},"subtitle":["A newer topical antibiotic"],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.4103\/0022-3859.113842","relation":{},"ISSN":["0022-3859"],"issn-type":[{"value":"0022-3859","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}